Integra Lifesciences Holdings (IART) Non-Current Debt (2016 - 2026)
Integra Lifesciences Holdings' Non-Current Debt history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.
- On a quarterly basis, Non-Current Debt rose 58.98% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 58.98% increase, with the full-year FY2025 number at $1.7 billion, up 58.98% from a year prior.
- Non-Current Debt hit $1.7 billion in Q4 2025 for Integra Lifesciences Holdings, up from $1.7 billion in the prior quarter.
- Over the last five years, Non-Current Debt for IART hit a ceiling of $1.7 billion in Q4 2025 and a floor of $733.1 million in Q4 2022.
- Historically, Non-Current Debt has averaged $1.0 billion across 5 years, with a median of $837.8 million in 2023.
- Biggest five-year swings in Non-Current Debt: decreased 18.28% in 2021 and later surged 58.98% in 2025.
- Tracing IART's Non-Current Debt over 5 years: stood at $824.3 million in 2021, then dropped by 11.05% to $733.1 million in 2022, then grew by 12.61% to $825.6 million in 2023, then skyrocketed by 31.78% to $1.1 billion in 2024, then skyrocketed by 58.98% to $1.7 billion in 2025.
- Business Quant data shows Non-Current Debt for IART at $1.7 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.1 billion in Q2 2025.